Ginkgo Bioworks Holdings, Inc. (DNA) stock
DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/3012% below fair value
$8.32−0.18 (-2.12%)
Close on Nov 17, 2026Market cap $560.27MP/E –Yield –
Ginkgo Bioworks total assets
Total assets on the balance sheet at the end of each period.
Ginkgo Bioworks's total assets was $990.05M at Jun 30, 2026. For fiscal 2025 it was $1.12B, down 18.7% from the year before. The highest annual figure on record is $2.54B in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.12B | -18.7% |
| FY2024 | Dec 31, 2024 | $1.38B | -17.3% |
| FY2023 | Dec 31, 2023 | $1.67B | -34.4% |
| FY2022 | Dec 31, 2022 | $2.54B | +22.6% |
| FY2021 | Dec 31, 2021 | $2.07B | +206.7% |
| FY2020 | Dec 31, 2020 | $675.15M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $990.05M | -19.6% |
| Q1 FY2026 | Mar 31, 2026 | $1.03B | -20.1% |
| Q4 FY2025 | Dec 31, 2025 | $1.12B | -18.7% |
| Q3 FY2025 | Sep 30, 2025 | $1.19B | -19.7% |
| Q2 FY2025 | Jun 30, 2025 | $1.23B | -24.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.29B | -18.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.38B | -17.3% |
| Q3 FY2024 | Sep 30, 2024 | $1.48B | -26.9% |
| Q2 FY2024 | Jun 30, 2024 | $1.63B | -29.1% |
| Q1 FY2024 | Mar 31, 2024 | $1.58B | -34.6% |
| Q4 FY2023 | Dec 31, 2023 | $1.67B | -34.4% |
| Q3 FY2023 | Sep 30, 2023 | $2.03B | +8.3% |
| Q2 FY2023 | Jun 30, 2023 | $2.29B | +14.9% |
| Q1 FY2023 | Mar 31, 2023 | $2.42B | +17.5% |
| Q4 FY2022 | Dec 31, 2022 | $2.54B | +22.6% |
| Q3 FY2022 | Sep 30, 2022 | $1.87B | -13.0% |
| Q2 FY2022 | Jun 30, 2022 | $1.99B | +15.5% |
| Q1 FY2022 | Mar 31, 2022 | $2.06B | +19.1% |
| Q4 FY2021 | Dec 31, 2021 | $2.07B | +206.7% |
| Q3 FY2021 | Sep 30, 2021 | $2.15B | – |
| Q2 FY2021 | Jun 30, 2021 | $1.73B | – |
| Q1 FY2021 | Mar 31, 2021 | $1.73B | – |
| Q4 FY2020 | Dec 31, 2020 | $675.15M | – |
See a number that looks wrong?